San-Qi Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7829911/publications.pdf

Version: 2024-02-01

		430874	501196
47	935	18	28
papers	citations	h-index	g-index

47	47	47	885
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. Journal of Medicinal Chemistry, 2022, 65, 4709-4726.	6.4	32
2	Menin-MLL protein-protein interaction inhibitors: a patent review (2014â€“2021). Expert Opinion on Therapeutic Patents, 2022, 32, 507-522.	5.0	11
3	Triazene as the Directing Group Achieving Highly Ortho-Selective Diborylation and Sequential Functionalization. Organic Letters, 2022, , .	4.6	4
4	Identification of benzamides derivatives of norfloxacin as promising microRNA-21 inhibitors via repressing its transcription. Bioorganic and Medicinal Chemistry, 2022, 66, 116803.	3.0	0
5	Synthesis and Biological Evaluation of 10â€Substituted Camptothecin Derivatives with Improved Water Solubility and Activity. ChemMedChem, 2021, 16, 1000-1010.	3.2	9
6	Small molecule selenium-containing compounds: Recent development and therapeutic applications. European Journal of Medicinal Chemistry, 2021, 223, 113621.	5.5	108
7	Recent Progress of Small Molecule Meninâ€“MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia. Journal of Medicinal Chemistry, 2021, 64, 15519-15533.	6.4	11
8	Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827. Anti-Cancer Drugs, 2021, 32, 417-426.	1.4	0
9	Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. European Journal of Medicinal Chemistry, 2020, 186, 111888.	5.5	43
10	Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). European Journal of Medicinal Chemistry, 2020, 189, 112061.	5.5	82
11	W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors. Investigational New Drugs, 2020, 38, 1218-1226.	2.6	3
12	Research advances on selective phosphatidylinositol 3 kinase Î´ (PI3KÎ´) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127457.	2.2	9
13	Discovery of potent small molecule PROTACs targeting mutant EGFR. European Journal of Medicinal Chemistry, 2020, 208, 112781.	5.5	58
14	K₂S₂O₈-promoted Câ€“Se bond formation to construct Î±-phenylseleno carbonyl compounds and Î±,Î²-unsaturated carbonyl compounds. RSC Advances, 2020, 10, 28902-28905.	3.6	6
15	F10, a new camptothecin derivative, was identified as a new orallyâ€“bioavailable, potent antitumor agent. European Journal of Medicinal Chemistry, 2020, 202, 112528.	5.5	15
16	Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy. International Journal of Oncology, 2020, 58, 70-82.	3.3	20
17	Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3KÎ´ inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 115035.	3.0	9
18	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 114930.	3.0	11

#	Article	IF	Citations
19	Cu-mediated selective bromination of aniline derivatives and preliminary mechanism study. Synthetic Communications, 2019, 49, 1406-1415.	2.1	10
20	The dual luciferase reporter system and RTâ€qPCR strategies for screening of MicroRNAâ€21 smallâ€molecule inhibitors. Biotechnology and Applied Biochemistry, 2019, 66, 755-762.	3.1	6
21	Metal-Free C-2-H Alkylation of Quinazolin-4-ones with Alkanes via Cross-Dehydrogenative Coupling. Organic Letters, 2019, 21, 2365-2368.	4.6	12
22	Synthesis of Aryl Trimethylstannane via BF₃Â·OEt₂-Mediated Cross-Coupling of Hexaalkyl Distannane Reagent with Aryl Triazene at Room Temperature. Journal of Organic Chemistry, 2019, 84, 463-471.	3.2	23
23	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3KÎ´) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2028-2040.	3.0	21
24	Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. European Journal of Medicinal Chemistry, 2018, 148, 221-237.	5.5	36
25	Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2173-2185.	3.0	26
26	Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3KÎ´) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 651-656.	5.2	7
27	Copper-Mediated monochlorination of anilines and nitrogen-containing heterocycles. Synthetic Communications, 2018, 48, 2708-2714.	2.1	4
28	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. Future Medicinal Chemistry, 2018, 10, 2445-2455.	2.3	7
29	Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2018, 26, 3619-3633.	3.0	14
30	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3KÎ´ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1972-1977.	2.2	21
31	Discovery of 2-(pyridin-2-yl)aniline as a directing group for the sp² Câ€“H bond amination mediated by cupric acetate. Organic and Biomolecular Chemistry, 2017, 15, 6622-6631.	2.8	11
32	Vasodilation and hypotension of a novel 3-benzylquinazolin- 4(3H)-one derivative via the inhibition of calcium flux. European Journal of Pharmacology, 2016, 791, 741-750.	3.5	4
33	Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4408-4413.	2.2	24
34	Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents. Bioorganic and Medicinal Chemistry, 2016, 24, 179-190.	3.0	19
35	Discovery of novel 2-benzylisoquinolin-1(2H)-ones as potent vasodilative agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5808-5812.	2.2	4
36	Modification of N -(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5- a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Bioorganic and Medicinal Chemistry, 2015, 23, 5662-5671.	3.0	12

#	Article	IF	Citations
37	Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2015, 96, 382-395.	5.5	33
38	Design, synthesis and antiproliferative activity evaluation of m -(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1730-1735.	2.2	14
39	Discovery of 4-benzoylamino-N-(prop-2-yn-1-yl)benzamides as novel microRNA-21 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 6510-6519.	3.0	21
40	Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. Bioorganic and Medicinal Chemistry, 2015, 23, 6477-6485.	3.0	39
41	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. Bioorganic and Medicinal Chemistry, 2015, 23, 7765-7776.	3.0	19
42	Synthesis and antitumor activity evaluation of 2-arylisoquinoline-1,3(2H,4H)-diones in vitro and in vivo. Medicinal Chemistry Research, 2014, 23, 1340-1349.	2.4	13
43	Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3739-3748.	3.0	26
44	Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. European Journal of Medicinal Chemistry, 2014, 75, 96-105.	5.5	34
45	Discovery of novel 3-benzylquinazolin-4(3 H)-ones as potent vasodilative agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5597-5601.	2.2	13
46	Synthesis and cytotoxic activity of diaryl urea derivatives with a 4-methylpiperazinylcarbonyl moiety. Medicinal Chemistry Research, 2013, 22, 3857-3862.	2.4	15
47	Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping. Bioorganic and Medicinal Chemistry, 2013, 21, 6956-6964.	3.0	16